Claims

1. A pharmaceutical formulation, comprising an aqueous solution of a glutamic acid buffer and an antibody comprising a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO: 10, and a light chain CDR3 comprising SEQ ID NO: 1-1 , wherein said antibody, or fragment thereof, specifically binds human IL-17 receptor A, and wherein:

a) said glutamic acid buffer comprises a glutamic acid concentration of 105-30 mM ± 0.2 mM;

b) said glutamic acid buffer comprises a pH of 4.84.5-5.2 ± 0.2;

c) said formulation further comprises 3 ± 0.22-4% proline (w/v) and 0.01 ± 0.0020.005-0.02% (w/v) polysorbate 20; and

d) said antibody is at a concentration of about 140100 to 150 mg/ml.

2. The pharmaceutical formulation according to claim 1, wherein the antibody or fragment thereof comprises a heavy chain variable domain sequence comprising SEQ ID NO:3 and a light chain variable domain sequence comprising SEQ ID NO:4.

3. The pharmaceutical formulation according to claim 1 or claim 2, wherein the antibody comprises a heavy chain sequence comprising SEQ ID NO: 1 and a light chain sequence comprising SEQ ID NO:2, or alternatively, a heavy chain sequence comprising SEQ ID NO: 12 and the light chain sequence comprising SEQ ID NO:2.

4. The pharmaceutical formulation according to any one of claims 1 to 3, further comprising an osmolarity of 275 to 325 osm.

5. The pharmaceutical formulation according to any one of claims 1 to 4, further comprising a viscosity of 5 to 7 cP at 25 degrees C.

~~6. The pharmaceutical formulation according to claims 1 to 5, comprising about 140 mg/mL of said antibody, formulated with 10 ± 0.2 mM glutamic acid, 3 ± 0.2% (w/v) L-proline, 0.01 ± 0.002% (w/v) polysorbate 20, pH 4.8 ± 0.2.~~

67. A pharmaceutical container, comprising a vessel and the pharmaceutical formulation of any of claims 1 to 56, wherein the vessel is a vial, bottle, pre-filled syringe, or pre-filled autoinjector syringe.

78. A kit, comprising one or more pharmaceutical containers according to claim 67 and instructions regarding the use thereof.

~~9. The use of an antibody for the manufacture of a medicament for the treatment of psoriasis in a human patient in need thereof, wherein said antibody is selected from the group consisting of:~~

~~a) an antibody comprising a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO: 10, and a light chain CDR3 comprising SEQ ID NO:1 1 , wherein said antibody, or fragment thereof, specifically binds human IL-17 receptor A;~~

~~b) an antibody comprising a heavy chain variable domain sequence comprising SEQ ID NO:3 and a light chain variable domain sequence comprising SEQ ID NO:4, wherein said antibody, or fragment thereof, specifically binds human IL-17 receptor A; and~~

~~c) an antibody comprising a heavy chain sequence comprising SEQ ID NO:1 and a light chain sequence comprising SEQ ID NO:2, or alternatively, a heavy chain sequence comprising SEQ ID NO: 12 and the light chain sequence comprising SEQ ID NO:2, and wherein the dose of said antibody is a single or divided 70 to 1,000 mg dose.~~

~~10. The use according to claim 9 , wherein a single or divided 70 to 280 mg dose of said antibody is administered at time "0" (the first administration), at one week post time "0" (week one), and then administered every two to four weeks following the week one administration.~~

~~11. The use according to claim 10, wherein a single or divided 140 mg dose of said antibody is administered at time "0" (the first administration), at one week post time "0" (week one), and then administered every two weeks to patients weighing less than or approximately equal to 100 kg, and wherein a single or divided dose of 280 mg of said antibody is administered at time "0" (the first administration), at one week post time "0" (week one), and then administered every two weeks to patients weighing greater than 100 kg.~~

~~12. The use according to any of claims 9 to 11, wherein the psoriasis is selected from the group consisting of:~~

~~a) plaque psoriasis;~~

~~b) moderate to severe plaque psoriasis;~~

c) chronic moderate to severe plaque psoriasis and said patients are candidates for systemic therapy or phototherapy; and

d) chronic moderate to severe plaque psoriasis and wherein said patients have failed to respond to, have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate, and psoralen plus ultraviolet-A phototherapy.

13. The use according to any of claims 9 to 12, wherein the medicament is in a pharmaceutical formulation comprising about 140 mg/mL of said antibody, formulated with 10 ± 0.2 mM glutamic acid, 3 ± 0.2% (w/v) L-proline, 0.01 ± 0.002% (w/v) polysorbate 20, pH 4.8 ± 0.2.

14. The use according to claim 13, wherein the medicament is administered subcutaneously, intradermally, intramusclularly, and/or intravenously.